(Q43601604)

25 November 2017

Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response (English)

1 reference

25 November 2017

0 references

1

1 reference

25 November 2017

Y C Wang

2

1 reference

25 November 2017

W Y Yu Younger

3

1 reference

25 November 2017

C H Lin

4

1 reference

25 November 2017

K H Yang

5

1 reference

25 November 2017

C J Hong

6

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

25 November 2017

Schizophrenia Research

1 reference

25 November 2017

49

1 reference

25 November 2017

53-58

1 reference

25 November 2017

1-2

1 reference

Perikaryal and synaptic localization of alpha 2A-adrenergic receptor-like immunoreactivity.

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Pharmacological prospects for alpha 2-adrenoceptor antagonist therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Subtypes of alpha 2-adrenoceptors: pharmacological and molecular biological evidence converge

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Reserpine impairs spatial working memory performance in monkeys: reversal by the alpha 2-adrenergic agonist clonidine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Clozapine-induced hypersalivation and the alpha 2 adrenoceptor

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Clonidine and the treatment of the opiate withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Involvement of the alpha2-adrenergic system in polydipsia in schizophrenic patients: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

The side-effects of clozapine: a four year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Putting the 'A' in atypical: does α2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Functional studies of the central catecholamines.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

Serotonin-6 receptor variant (C267T) and clinical response to clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900127-4

7 January 2021

10.1016/S0920-9964(00)00127-4

Identifiers

DOI

1 reference

25 November 2017

1 reference